76%
jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti.
76%
jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse.
Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
76%
jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti.
76%
jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse.
Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
iRhythm Technologies Inc
Suletud
SektorTervishoid
140.76 0.21
Ülevaade
Aktsiahinna muutus
24h
Min
136.66
Max
141.75
Sissetulek | -29M -31M |
|---|---|
Müük | -5.6M 159M |
Aktsiakasum | -0.95 |
Kasumimarginaal | -19.347 |
Töötajad | 2,000 |
EBITDA | -28M -33M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | -1.38% downside |
Järgmine tulemuste avaldamine | 31. juuli 2025 |
|---|
Turukapital | 995M 4.4B |
|---|---|
Eelmine avamishind | 140.55 |
Eelmine sulgemishind | 140.76 |
Uudiste sentiment
By Acuity
50%
50%
173 / 382 Pingereas Healthcare
Tehniline skoor
By Trading Central
Kindlus
Bullish Evidence
iRhythm Technologies Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
iRhythm Technologies Inc Prognoos
Hinnasiht
By TipRanks
-1.38% langus
12 kuu keskmine prognoos
Keskmine 139.1 USD -1.38%
Kõrge 151 USD
Madal 130 USD
Põhineb 11 Wall Streeti analüütiku instrumendi iRhythm Technologies Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Sentiment
By Acuity
173 / 382 Pingereas Tervishoid
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest iRhythm Technologies Inc
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
